Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy , although not significant in the sunitinib-to-axitinib sequence subgroup ; OS was also longer in patients with smaller tumour burden , but not significant in the cytokine-to-axitinib sequence subgroup .